A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight
NCT ID: NCT04657003
Last Updated: 2024-04-08
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
938 participants
INTERVENTIONAL
2021-03-29
2023-04-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program
NCT04657016
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight
NCT04184622
A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity
NCT06037252
A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
NCT06047548
A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)
NCT07247084
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
10 milligrams (mg) Tirzepatide
10 mg Tirzepatide administered subcutaneously (SC) once weekly (QW)
Tirzepatide
Administered SC
15 mg Tirzepatide
15 mg Tirzepatide administered SC QW
Tirzepatide
Administered SC
Placebo
Placebo administered SC QW
Placebo
Administered SC
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tirzepatide
Administered SC
Placebo
Administered SC
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have a BMI of ≥27 kg/m²
* Are overweight or have obesity
* Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight
* Are at least 18 years of age and age of majority per local laws and regulations
Exclusion Criteria
* Have at least 2 confirmed fasting self-monitoring blood glucose (SMBG) values \>270 mg/dL(on 2 nonconsecutive days) prior to Visit 3
* Have proliferative diabetic retinopathy OR diabetic macular edema OR non-proliferative diabetic retinopathy that requires acute treatment
* Have self-reported change in body weight \>5kg within 3 months prior to screening
* Have had a history of chronic or acute pancreatitis
* Change in body weight greater than 5 kg within 3 months prior to starting study
* Obesity induced by other endocrinologic disorders or monogenetic or syndromic forms of obesity
* Family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
* History of significant active or unstable major depressive disorder (MDD) or other severe psychiatric disorder within the last 2 years
* Any lifetime history of a suicide attempt
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eli Lilly and Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Role: STUDY_DIRECTOR
Eli Lilly and Company
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Loema Instituto de Pesquisa Clinica
Campinas, São Paulo, Brazil
Instituto de Pesquisa clinica de Campinas
Campinas, São Paulo, Brazil
University of Alabama - Department of Nutrition Sciences
Birmingham, Alabama, United States
KLR Business Group, Inc. dba Arkansas Clinical Research
Little Rock, Arkansas, United States
Velocity Clinical Research, Huntington Park
Huntington Park, California, United States
Velocity Clinical Research, Westlake
Los Angeles, California, United States
Catalina Research Institute, LLC
Montclair, California, United States
Encompass Clinical Research
Spring Valley, California, United States
University Clinical Investigators, Inc.
Tustin, California, United States
ALL Medical Research, LLC
Cooper City, Florida, United States
Northeast Research Institute (NERI)
Fleming Island, Florida, United States
New Horizon Research Center
Miami, Florida, United States
West Orange Endocrinology
Ocoee, Florida, United States
Metabolic Research Institute, Inc.
West Palm Beach, Florida, United States
Emory University School of Medicine- Grady Campus
Atlanta, Georgia, United States
East Coast Institute for Research, LLC
Macon, Georgia, United States
Pacific Diabetes & Endocrine Center
Honolulu, Hawaii, United States
Elite Clinical Trials
Blackfoot, Idaho, United States
Rocky Mountain Clinical Research
Idaho Falls, Idaho, United States
American Health Network of Indiana, LLC - Greenfield
Greenfield, Indiana, United States
Iowa Diabetes and Endocrinology Research Center
West Des Moines, Iowa, United States
Cotton O'Neil Clinical Research Center
Topeka, Kansas, United States
Maryland Cardiovascular Specialists
Baltimore, Maryland, United States
MD Medical Research
Oxon Hill, Maryland, United States
NECCR PrimaCare Research
Fall River, Massachusetts, United States
Arcturus Healthcare , PLC, Troy Internal Medicine Research Division
Troy, Michigan, United States
Logan Health Research
Kalispell, Montana, United States
Premier Research
Trenton, New Jersey, United States
University of North Carolina Medical Center
Chapel Hill, North Carolina, United States
PharmQuest
Greensboro, North Carolina, United States
Wake Forest University Baptist Medical Center (WFUBMC)
Winston-Salem, North Carolina, United States
Velocity Clinical Research, Cleveland
Cleveland, Ohio, United States
Aventiv Research
Dublin, Ohio, United States
The Corvallis Clinic, P.C.
Corvallis, Oregon, United States
Preferred Primary Care Physicians
Uniontown, Pennsylvania, United States
Center for Neurosciences
Warwick, Rhode Island, United States
Tribe Clinical Research, LLC
Greenville, South Carolina, United States
Texas Diabetes & Endocrinology, P.A.
Austin, Texas, United States
Dallas Diabetes Research Center
Dallas, Texas, United States
Diabetes and Thyroid Center of Fort Worth
Fort Worth, Texas, United States
Juno Research
Houston, Texas, United States
Endocrine Ips, Pllc
Houston, Texas, United States
Health Research of Hampton Roads, Inc.
Newport News, Virginia, United States
Rainier Clinical Research Center
Renton, Washington, United States
Clinical Investigation Specialists
Kenosha, Wisconsin, United States
Consultorio de Investigación Clínica EMO SRL
Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina
Centro de Investigaciones Metabólicas (CINME)
Ciudad Autónoma de Buenos Aire, Buenos Aires, Argentina
Instituto de Investigaciones Clínicas Mar del Plata
Mar del Plata, Buenos Aires, Argentina
Go Centro Medico San Nicolás
San Nicolás de los Arroyos, Buenos Aires, Argentina
Centro Médico Viamonte
Buenos Aires, Ciudad Autónoma de Buenos Aire, Argentina
CIPREC
CABA, Ciudad Autónoma de Buenos Aire, Argentina
Centro de Investigaciones Médicas Tucuman
SAN M. de Tucuman, Tucumán Province, Argentina
Sanatorio Norte
Santiago del Estero, , Argentina
Private Practice - Dr.Miguel N. Hissa
Fortaleza, Ceará, Brazil
CECIP - Centro de Estudos do Interior Paulista
Jaú, São Paulo, Brazil
CPCLIN
São Paulo, São Paulo, Brazil
CEPIC - Centro Paulista de Investigação Clínica
São Paulo, , Brazil
Life Care Hospital and Research Centre
Bangalore, Karnataka, India
ILS Hospitals
Kolkata, West Bengal, India
Medical Corporation Yuga Tsuruma Kaneshiro Diabetes Clinic
Yamato-shi, Kanagawa, Japan
Medical Corporation Heishinkai OCROM Clinic
Suita-shi, Osaka, Japan
Medical Corporation Sato Medical clinic
Ootaku, Tokyo, Japan
AMC Nishiumeda Clinic
Osaka, , Japan
Centro de Endocrinologia y Nutricion
Caguas, , Puerto Rico
Latin Clinical Trial Center
San Juan, , Puerto Rico
GCM Medical Group, PSC - Hato Rey Site
San Juan, , Puerto Rico
Endocrinology Research Center of Rosmedtechnologies
Moscow, Moscow, Russia
Russian Medical Academy of Postgraduate Education
Moscow, Moscow, Russia
Saint-Petersburg City Hospital of Saint Elizabeth
Saint Petersburg, Sankt-Pete, Russia
Smolensk State Medical University
Smolensk, , Russia
Changhua Christian Hospital
Changhua County, Changhua, Taiwan
Chi Mei Medical Center
Tainan City, Tainan, Taiwan
Chung Shan Medical University Hospital
Taichung, , Taiwan
Taichung Veterans General Hospital
Taichung, , Taiwan
National Cheng-Kung Uni. Hosp.
Tainan City, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Heerspink HJL, Friedman AN, Bjornstad P, van Raalte DH, Cherney D, Cao D, Garcia-Perez LE, Stefanski A, Turfanda I, Bunck MC, Benabbad I, Griffin R, Piras de Oliveira C. Kidney Parameters with Tirzepatide in Obesity with or without Type 2 Diabetes. J Am Soc Nephrol. 2025 Jun 13. doi: 10.1681/ASN.0000000764. Online ahead of print. No abstract available.
Hunter Gibble T, Cao D, Zhang XM, Xavier NA, Poon JL, Fitch A. Tirzepatide Was Associated with Improved Health-Related Quality of Life in Adults with Obesity or Overweight and Type 2 Diabetes: Results from the Phase 3 SURMOUNT-2 Trial. Diabetes Ther. 2025 May;16(5):977-991. doi: 10.1007/s13300-025-01723-w. Epub 2025 Mar 22.
Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, Mao H, Zhang S, Ahmad NN, Bunck MC, Benabbad I, Zhang XM; SURMOUNT-2 investigators. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023 Aug 19;402(10402):613-626. doi: 10.1016/S0140-6736(23)01200-X. Epub 2023 Jun 26.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight (SURMOUNT-2)
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
I8F-MC-GPHL
Identifier Type: OTHER
Identifier Source: secondary_id
17245
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.